Advanced Bitcoin Technologies AG Q4 FY2023 Earnings Call

· Earnings call transcript and AI-powered summary

  • Q4 Organic Sales: +2.1% (includes COVID testing decline; base business grew 11%).
  • FY 2023 Performance:
    • Ex-COVID Organic Sales Growth: >11%, outperforming original high-single-digit guidance.
    • Adjusted Earnings Per Share (EPS): $4.44, above midpoint of guidance despite lower-than-expected COVID revenue.
  • FY 2024 Guidance:
    • Base Business Organic Sales Growth: 8% to 10% (translates to over $3B in growth).
    • Adjusted EPS: $4.50 – $4.70 (Q1 EPS forecast: $0.93 – $0.97).
    • Expected FX Impact: -1% full-year; -2% Q1.

Business Segment Highlights (Q4 2023)

  • Nutrition: +14% sales growth; U.S. Pediatric Nutrition regained market leadership. Adult Nutrition grew 13.5%, with Ensure and Glucerna leading.
  • Established Pharmaceuticals (EPD): +9% in Q4 (11% full-year). Achieved third straight year of double-digit growth with expansion in biosimilars.
  • Diagnostics:
    • Core Lab: +10% growth, driven by Alinity system success and high retention.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good morning, and thank you for standing by. Welcome to Abbott's Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations. Michael Comilla: Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; Bob Funck, Executive Vice President, Finance; and Phil Boudreau, Senior Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2024. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10-K for the year ended D

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional